Medtronic Veteran Joins CorFlow Therapeutics: What Caught His Eye?

Registration: First Global Cardiovascular Conference| Latest Agenda

Call for Partners: 2025 Global Surgical Robotics Conference

On May 9, 2025, CorFlow Therapeutics, an innovative cardiovascular medical device company, announced the appointment of Chris O’Connell as Chairman of the Board, succeeding Rick Geoffrion.

This personnel change is not simple. Chris O’Connell's career history is highly condensed.Global Medical Device "Head Experience": He is inWorked at Medtronic for 21 years, who successively led the cardiovascular, diabetes, and restorative therapy divisions, was a core member of the executive committee during Medtronic's golden age of expansion; later, he served as the president and CEO of Waters Corporation for five years, leading the company to achieve dual growth in revenue and market value.

In the past few years, Chris has served as an independent director on the boards of several medical device and life sciences companies. But this time, he has chosen to "take a seat at the table" at CorFlow, assuming the role of chairman of the board.

From a global giant to a company whose procedures are still in the experimental stage, this is not an easy decision.

What exactly has CorFlow done to make such a veteran in the industry willing to take a bet?

# CoFI: From "Intraoperative Invisible MVO" to Real-Time Diagnosis + Local Treatment

The core platform of CorFlow isControlled Flow Infusion (CoFI) System`, focusing on`Microvascular Obstruction (MVO)TheIntraoperative Identification and Targeted TherapyMVO is common in patients with acute myocardial infarction. Even after completing coronary revascularization (PCI), long-term adverse outcomes may still occur due to microvascular perfusion disorders.

The current mainstream interventional approaches still lack tools that can identify MVO in real time and intervene immediately; CoFI aims to fill this gap.

The system is composed ofPressure-sensing guidewires, catheters with infusion and occlusion functions, consoles, and disposable cartridgesComposition, equipped with proprietary algorithms, can evaluate distal vascular pressure response in real time during surgery and calculate the MVO risk parameters. The entire systemCompatible0.014 Guidewire PathAnd6Fr Guiding Catheter, can be seamlessly integrated into existing PCI procedures.

In addition, CoFI also supports local drug delivery treatment, which enables drugs to penetrate through the microvascular obstruction area via controlled "massage-like" injection, with the potential to improve reperfusion quality. Early data released at the 2023 EuroPCR conference showed:

• MVO detection sensitivity reaches 95%, specificity reaches 91%.

• The test results showed a significant correlation with the myocardial injury area and obstruction range displayed by CMRI.

• No device-related deaths or serious complications reported within 30 days.

This kind of "intraoperative identification + immediate treatment" approach is not common in coronary interventions. Chris O’Connell remarked in the joining announcement, “What CorFlow has created is a truly platform born out of unmet clinical needs, and it’s worth the effort.”

# Two Core Clinical Trials Advancing, Series B Financing Oversubscribed by Top-Tier Funds

CorFlow is currently advancing two clinical trials simultaneously:

• FDA IDE Registration Trial in the United States, led by Professor Tim Henry of Cincinnati Christ Hospital, intended to support marketing authorization;

• European RCT Randomized Controlled Trial, conducted in collaboration between the University of Oxford and the University of Glasgow, to evaluate its intervention outcomes.

These two tests correspond to"Accuracy Verification" of Intraoperative MVO DiagnosisAnd"Efficacy Evaluation" of Treatment Interventions, forming the key evidence system for CorFlow's future commercial path.

September 2024,Company Completed44 MillionEuro B Round Financing, byLed by Broadview Ventures, Panakes Partners, and participated by well-known medical technology funds such as Merieux Equity, Wellington, and 415 Capital, the round was oversubscribed.

# Why Does a Startup Attract a Medtronic Veteran?

Chris's background is not simple. During his time at Medtronic, he led the development of multiple surgical product lines; during his tenure at Waters, he had a deep understanding of operations, mergers and acquisitions, and growth strategies.

And now, he has chosen to join CorFlow.

The judgment behind this may not just be about a certain technology, but rather about seeing three things:

• A surgical approach that has not yet been standardized but is of great clinical concern (intraoperative MVO identification and treatment);

• A technology platform that has accumulated clinical evidence and completed global financing validation;

• A core team believed to have the opportunity to "advance a step" in surgical procedures.

In the field of cardiovascular medicine, MVO has long been referred to as "the final blind spot of PCI procedures." What CorFlow aims to do is to illuminate this blind spot.

# AboutCorFlow Therapeutics

CorFlow Therapeutics is a medical device company focused on developing diagnostic and therapeutic solutions for microvascular obstruction (MVO) following myocardial infarction. The company has established partnerships with several renowned institutions and enterprises. In September 2024, the company completed a €44 million Series B financing round.